Viking Therapeutics SG&A Expense (Quarterly) Analysis

Viking Therapeutics Inc (VKTX)

79.57 +4.15 (+5.50%) USD | NASDAQ | Apr 30, 16:00

78.20 -1.37 (-1.72%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2012. Upgrade now.

Date	Value
March 31, 2024	9.97M
December 31, 2023	8.783M
September 30, 2023	8.886M
June 30, 2023	9.823M
March 31, 2023	9.529M
December 31, 2022	4.105M
September 30, 2022	4.237M
June 30, 2022	4.089M
March 31, 2022	3.69M
December 31, 2021	2.663M
September 30, 2021	2.608M
June 30, 2021	2.737M
March 31, 2021	2.693M
December 31, 2020	2.217M
September 30, 2020	2.727M
June 30, 2020	2.826M
March 31, 2020	2.961M
December 31, 2019	2.422M
September 30, 2019	2.16M
June 30, 2019	2.236M
March 31, 2019	2.31M
December 31, 2018	1.948M

Date	Value
September 30, 2018	1.707M
June 30, 2018	1.704M
March 31, 2018	1.762M
December 31, 2017	1.394M
September 30, 2017	1.227M
June 30, 2017	1.267M
March 31, 2017	1.441M
December 31, 2016	1.090M
September 30, 2016	1.160M
June 30, 2016	1.207M
March 31, 2016	1.390M
December 31, 2015	1.401M
September 30, 2015	1.781M
June 30, 2015	1.526M
March 31, 2015	0.3221M
December 31, 2014	0.2108M
September 30, 2014	0.3604M
June 30, 2014	0.514M
March 31, 2014	0.1597M
June 30, 2013	0.0136M
March 31, 2013	0.0026M
December 31, 2012	0.0408M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

2.16M

Minimum

Sep 2019

9.97M

Maximum

Mar 2024

4.568M

Average

2.894M

Median

SG&A Expense (Quarterly) Benchmarks